Skip to main content

NCT00968812 - A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus

A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled on Metformin Monotherapy


Data Specification

Annotated CRF

Available upon data request approval

Product Info

Generic Name
Canagliflozin
Product Name
INVOKANA®
Therapeutic Area
Nutritional and Metabolic Diseases
Enrollment
1,452
% Female
48.0%
% White
67.0%
Product Class
Diabetes Related- Other
Sponsor Protocol Number
28431754DIA3009
Data Partner
Johnson & Johnson
Condition Studied
Diabetes Mellitus, Type 2
Mean/Median Age (Years)
57.0

Supporting Documentation

Clinical Study Report
Collected Datasets
Data Definition Specification
Annotated Case Report Form
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
3

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.